<DOC>
	<DOCNO>NCT02449343</DOCNO>
	<brief_summary>Compare effect safety Anlotinib placebo patient soft tissue sarcoma .</brief_summary>
	<brief_title>Study Anlotinib Patients With Soft Tissue Sarcoma（STS） ( ALTER0203 )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Signed date informed consent Histological documentation Soft Tissue Sarcoma , include Synovial sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma，With measurable disease . Within past 6 month , use least one failure chemotherapy regimen ( include anthracyclinebased ) treat patient ( except alveolar soft part sarcoma ) 1870years , ECOG PS:01 , Life expectancy 3 month Main organ function normal The woman patient childbearing age must agree take contraceptive method ( e.g . intrauterine device , contraceptive pill condom ) research within another 6 month ; lactation period examine negative blood serum test urine pregnancy test within 7 day research ; The man patient must agree take contraceptive method research within another 6 month Prior treatment Anlotinib With pleural effusion ascites , cause respiratory syndrome Accepted vascular endothelial growth inhibitor class target drug treatment patient Plan take systemic antitumor therapy within 4 week group medicinetaking period research , include Cytotoxic Therapy , Signal Transduction Inhibitor , Immunotherapy ( use Mitomycin C within 6 week take treatment experimental drug ) ; The patient already take Extended Field Radiotherapy ( EFRT ) within 4 week group Limited Field Radiotherapy propose assessment nidus within 2 week group Symptoms brain metastasis control treat within less 2 month With severe fail controlled disease Occurred venous thromboembolic event within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>